Platinum open access journal
pISSN 2466-0493 eISSN 2466-054X
Indexed in MEDLINE, SCIE, Scopus, DOAJ and more
    Korean J Urol. 2009 Feb;50(2):148-153. Korean.
    Published online Feb 25, 2009.
    https://doi.org/10.4111/kju.2009.50.2.148
    Copyright © The Korean Urological Association, 2009
    Original Article

    Comparison of the Efficacy of a Terpene Mixture and Alpha-Blocker for Treatment of Category III Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Prospective Study

    Woo Heon Cha, Ki Ho Kim and Young Jin Seo
      • Department of Urology, College of Medicine, Dongguk University, Gyeongju, Korea.
    • Correspondence to: Young Jin Seo. Department of Urology, College of Medicine, Dongguk University, 1090-1, Seokjang-dong, Gyeongju 780-350, Korea. TEL: 054-770-8265, FAX: 054-771-0769, Email: seoyjin@korea.co
    Received August 04, 2008; Accepted September 08, 2008.

    Abstract

    Purpose

    The aim of this study was to evaluate the efficacy of a terpene mixture compared with alpha-blocker in patients with chronic pelvic pain syndrome (CPPS).

    Materials and Methods

    Patients diagnosed with CPPS were included in this study. The patients were randomly placed into three groups. Group 1 was treated with levofloxacin alone (36 patients), group 2 was treated with levofloxacin and alfuzosin (33 patients), and group 3 was treated with levofloxacin and terpene mixture (34 patients) for 8 weeks. The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) was evaluated in patients in each group at the beginning of the study and after 8 weeks of treatment.

    Results

    Pain domain, urinary domain, quality of life domain, and total score on the NIH-CPSI were not significantly different at the initial visit. After treatment with each medication, improvements on the pain domain and total score of the NIH-CPSI were better in group 3 than in group 1 or group 2 (p<0.05). Improvement on the urinary domain of the NIH-CPSI was better in group 2 than in group 1 or group 3 (p=0.014). Changes in the quality of life domain of the NIH-CPSI were not significant among the three groups.

    Conclusions

    This study suggests that the terpene mixture and alpha-blockers may have significant benefit for symptomatic relief, especially in the pain and urinary domains, respectively.

    Keywords
    Pelvic pain; Adrenergic alpha-antagonists; Terpenes

    Figures

    Fig. 1
    Mean value of the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) pain domain score (potential of 21 points) at the beginning of the study and after 8 weeks of treatment in each group.

    Fig. 2
    Mean value of the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) urinary domain score (potential of 10 points) at the beginning of the study and after 8 weeks of treatment in each group.

    Fig. 3
    Mean value of the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) quality of life domain score (potential of 12 points) at the beginning of the study and after 8 weeks of treatment in each group.

    Fig. 4
    Mean value of the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score (potential of 43 points) at the beginning of the study and after 8 weeks of treatment in each group.

    Tables

    Table 1
    Baseline patient characteristics

    References

      1. Alexander RB, Propert KJ, Schaeffer AJ, Landis JR, Nickel JC, O'Leary MP, et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Ann Intern Med 2004;141:581–589.
      1. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999;282:236–237.
      1. Nickel JC, Nyberg LM, Hennenfent M. Research guidelines for chronic prostatitis: consensus report from the first national institutes of health international prostatitis collaborative network. Urology 1999;54:229–233.
      1. Lee CB, Ha US, Lee SJ, Kim SW, Cho YH. Preliminary experience with a terpene mixture versus ibuprofen for treatment of category III chronic prostatitis/chronic pelvic pain syndrome. World J Urol 2006;24:55–60.
      1. Bartoletti R, Cai T, Mondaini N, Dinelli N, Pinzi N, Pavone C, et al. Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multicenter case-control observational study. J Urol 2007;178:2411–2415.
      1. Woo YN. Prostatitis. Korean J Urol 1994;35:575–585.
      1. Kirby RS. Surgical considerations in the management of prostatitis. In: Nickel JC, editor. Textbook of prostatitis. Oxford: ISIS Medical Media Ltd; 1999. pp. 346-364.
      1. Roberts RO, Lieber MM, Rhodes T, Girman CJ, Bostwick DG, Jacobsen SJ. Prevalence of a physician-assigned diagnosis of prostatitis: The Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology 1998;51:578–584.
      1. Ku JH, Kim ME, Lee NK, Park YH. The prevalence of chronic prostatitis-like symptoms in young men: a community-based survey. Urol Res 2001;29:108–112.
      1. Moon TD, Hagen L, Heisey DM. Urinary symptomatology in younger men. Urology 1997;50:700–703.
      1. Mehik A, Hellstrom P, Lukkarinen O, Sarpola A, Jarvelin M. Epidemiology of prostatitis in Finnish men: a population-based cross-sectional study. BJU Int 2000;86:443–448.
      1. Shoskes DA, Hakim L, Ghoniem G, Jackson CL. Long-term results of multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome. J Urol 2003;169:1406–1410.
      1. McNaughton Collins M, MacDonald R, Wilt TJ. Diagnosis and treatment of chronic abacterial prostatitis: a systematic review. Ann Intern Med 2000;133:367–381.
      1. Nickel JC, Pontari M, Moon T, Gittelman M, Malek G, Farrington J, et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. J Urol 2003;169:1401–1405.
      1. Goto T, Makinose S, Ohi Y, Yamauchi D, Kayajima T, Nagayama K, et al. Diffusion of piperacillin, cefotiam, minocycline, amikacin, and ofloxacin into the prostate. Int J Urol 1998;5:243–246.
      1. Nickel JC, Downey J, Johnston B, Clark J, Canadian Prostatitis. Predictors of patient response to antibiotic therapy for the chronic prostatitis/chronic pelvic pain syndrome: a prospective multicenter clinical trial. J Urol 2001;165:1539–1544.
      1. Mo KI, Lee KS, Kim DG. Efficacy of combination therapy for patients with chronic prostatitis/chronic pelvic pain syndrome: a prospective study. Korean J Urol 2006;47:536–540.
      1. Donker PJ, Ivanovici F, Noach EL. Analyses of the urethral pressure profile by means of electromyography and the administration of drugs. Br J Urol 1972;44:180–193.
      1. Barbalias GA, Nikiforidis G, Liatsikos EN. Alpha-blockers for the treatment of chronic prostatitis in combination with antibiotics. J Urol 1998;159:883–887.
      1. Cheah PY, Liong ML, Yuen KH, Teh CL, Khor T, Yang JR, et al. Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology 2004;64:881–886.
      1. Youn CW, Son KC, Choi HS, Kwon DD, Park K, Ryu SB. Comparison of the efficacy of antibiotic monotherapy and antibiotic plus alpha-blocker combination therapy for patients with inflammatory chronic prostatitis/chronic pelvic pain syndrome. Korean J Urol 2008;49:72–76.
      1. Nickel JC, Narayan P, McKay J, Doyle C. Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. J Urol 2004;171:1594–1597.
      1. Ryu YG, Kim HJ, Park HJ. The efficacy of alfuzosin for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. Korean J Urol 2007;48:858–862.
      1. Dedhia RC, McVary KT. Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2008;179:2119–2125.
      1. Siller G. Effect of rowatinex capsules on the stone fragments formed by extracorporeal shock-wave lithotripsy. Magyar Urol 1998;10:139–146.
      1. Zhou JY, Tang FD, Mao GG, Bian RL. Effect of alpha-pinene on nuclear translocation of NF-kappa B in THP-1 cells. Acta Pharmacol Sin 2004;25:480–484.
      1. Park TJ, Park YS, Lee TG, Ha H, Kim KT. Inhibition of acetylcholine-mediated effects by borneol. Biochem Pharmacol 2003;65:83–90.
      1. Juergens UR, Stober M, Vetter H. Inhibition of cytokine production and arachidonic acid metabolism by eucalyptol (1.8-cineole) in human blood monocytes in vitro. Eur J Med Res 1998;3:508–510.
      1. Minnery CH, Getzenberg RH. Benign prostatic hyperplasia cell line viability and modulation of jm-27 by doxazosin and ibuprofen. J Urol 2005;174:375–379.
      1. Bak CW, Yoon SJ, Chung H. Effects of an α-blocker and terpene mixture for pain control and spontaneous expulsion of ureter stone. Korean J Urol 2007;48:517–521.
    Cited by
    Crossref 4
    Google Scholar 
    Scopus 4
    MeSH Terms
    Adrenergic alpha-Antagonists
    Humans
    National Institutes of Health (U.S.)
    Ofloxacin
    Pelvic Pain
    Prospective Studies
    Prostatitis
    Quality of Life
    Quinazolines
    Terpenes
    Metrics
    Share
    Figures
    slide
    slide
    slide
    slide

    1 / 4

    Tables
    slide

    1 / 1

    PERMALINK